Curaleaf announced its intention to launch a takeover bid for all outstanding Aurora Cannabis shares at US$4.00 each — 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash. The total outlay is roughly $272 million. Curaleaf said attempts to engage privately did not lead to substantive discussions and is taking the offer directly to shareholders. Aurora's board formed a special committee to evaluate the proposal.
Aurora shares closed up 20.59% at $3.485.
The offer
| Term | Detail |
|---|---|
| Headline price | US$4.00 per Aurora share |
| Consideration | 0.3463 Curaleaf shares + US$0.75 cash |
| Total value | ~$272M |
| Premium to 30-day VWAP ($2.75) | 45% |
| Premium excluding Aurora's cash | 110% |
| Combined footprint | 17 countries |
| Combined TTM revenue | >$1.5B |
| Combined adjusted EBITDA | ~$350M |
Read the two premium numbers together
The gap between 45% and 110% is the most informative disclosure in the announcement, and it is the one written to be skimmed past.
A 45% premium is calculated against Aurora's whole share price. The 110% figure is calculated after stripping out the cash sitting on Aurora's balance sheet. The difference tells you that a large share of Aurora's market value is simply money in the bank rather than the value of the operating business.
Which reframes the offer. Measured against what Aurora actually does — cultivation, medical cannabis distribution, international supply — the bid is generous. Measured against what Aurora has, an acquirer is proposing to hand over its own stock in exchange for a business plus that cash pile.
Curaleaf chose to publish both numbers because the second one is its argument to Aurora shareholders: the market is valuing your company as a bank account, and we will pay you for the operations too.
What shareholders are actually being asked to accept
Seventy-five cents in cash, and the rest in Curaleaf paper.
That is the crux. Aurora holders are not being offered an exit at $4.00; they are being offered $0.75 plus a position in a different cannabis company at a fixed exchange ratio. The value of the deal moves with Curaleaf's share price between now and closing, and the sector's equity has been anything but stable.
For a board, the question is not whether $4.00 beats $2.75 today. It is whether 0.3463 of a Curaleaf share is worth more than a standalone Aurora share in two years, including the cash Aurora currently controls and the combined entity would spend.
The industrial logic is genuine: 17 countries, over $1.5 billion of revenue and roughly $350 million of adjusted EBITDA make a legitimate global leader in a sector where scale has been the missing ingredient. Cannabis has too many subscale companies carrying full public-company costs, and consolidation is the rational endgame.
How I read it
This is a distressed-sector consolidation attempt priced off a depressed VWAP, paid mostly in the acquirer's own equity, aimed at a target whose cash is a meaningful part of the prize.
For Aurora holders, the +20.6% close — still well below the $4.00 offer — is the market pricing a probability, not an outcome. Hostile bids at these premiums frequently end in a negotiated price above the opening number, or in nothing at all.
For Curaleaf holders, the question is dilution against synergy — and the honest answer is that cannabis integrations have a poor record of delivering the second while reliably delivering the first.
What I would watch: whether a competing bidder emerges, and how Aurora's board frames the cash in its formal response. If the defence leans on the balance sheet, the price goes up. If it leans on strategy, this deal probably gets done near $4.00.